Retrieve available abstracts of 378 articles: HTML format
Single Articles
May 2025
WAGAR MK, Reetz E, Huang D, Kao MJ, et al Patterns of primary metastasis and recurrence in mismatch repair deficiency and
p53 abnormal endometrial carcinoma.
Gynecol Oncol. 2025;197:171-178. PubMedAbstract available
WAGGONER RM, Mahoney RP, Nathan D, Zell JA, et al Assessing preventive gynecologic decisions in individuals with Lynch syndrome.
Gynecol Oncol. 2025;197:163-170. PubMedAbstract available
BYRNE ME, Selenica P, Dessources K, Da Cruz Paula A, et al Peritoneal washings analysis in endometrial cancer: Comparison of somatic
mutation detection with panel sequencing and traditional cytology.
Gynecol Oncol. 2025;197:155-162. PubMedAbstract available
XIAO Y, Pang J, Zhou Y, Lu J, et al FRalpha expression in advanced endometrial carcinoma: Clinicopathological, molecular,
and prognosis correlates.
Gynecol Oncol. 2025;197:146-154. PubMedAbstract available
EVANS E, Dholakia J, Abraham J, Hinton A, et al Whole-exome sequencing provides assessment of homologous recombination deficiency
for identification of PARPi-responsive ovarian tumors.
Gynecol Oncol. 2025;197:139-145. PubMedAbstract available
MOUFARRIJ S, Dopeso H, Brown DN, Green H, et al TROP2 expression and therapeutic targeting in uterine carcinosarcoma.
Gynecol Oncol. 2025;197:129-138. PubMedAbstract available
KARLSSON E, Vorobii O, Silins I, Sundstrom Poromaa I, et al Splenectomy as an indicator for ovarian cancer spread and complete cytoreduction.
Gynecol Oncol. 2025;197:121-128. PubMedAbstract available
KEVERLINE KJ, Hill B, Hom-Tedla M, Jacobs M, et al Impact of mismatch repair (MMR) status on recurrence in high intermediate risk
endometrial cancer.
Gynecol Oncol. 2025;197:116-120. PubMedAbstract available
ETTORRE VM, Bellone S, Greenman M, McNamara B, et al A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic
endometrial cancers with microsatellite instability (NCT02899793): Updated
survival and response analyses.
Gynecol Oncol. 2025;197:110-115. PubMedAbstract available
SUH-BURGMANN E, Hung YY, Finertie H, Zhong H, et al Association of endometrial cancer epigenetic mismatch repair deficiency with
clinicopathologic factors and survival in a large, diverse community-based
cohort.
Gynecol Oncol. 2025;197:102-109. PubMedAbstract available
April 2025
LOUKOVAARA M, Pasanen A, Butzow R Molecular subgroup-specific prognostic value of semiquantitative lymphovascular
space invasion in early-stage endometrioid endometrial cancer.
Gynecol Oncol. 2025;197:96-101. PubMedAbstract available
BAE J, Kim U, Paik ES, Lim MC, et al Oncologic outcomes of minimally invasive surgery vs. abdominal hysterectomy in
patients with low-risk, early-stage cervical cancer: A retrospective analysis of
KGOG 1028 data based on SHAPE trial eligibility criteria.
Gynecol Oncol. 2025;197:91-95. PubMedAbstract available
JOHNSON CR, Aryasomayajula C, Francoeur AA, Stewart C, et al Pathogenic germline variants among women with uterine cancer by ancestry: A
commercial laboratory collaborative research registry study.
Gynecol Oncol. 2025;197:83-90. PubMedAbstract available
POVEDA A, Lheureux S, Colombo N, Cibula D, et al Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed
ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall
survival results from the OPINION trial.
Gynecol Oncol. 2025;197:74-82. PubMedAbstract available
YOU B, Anderson C, Cecere SC, Carrot A, et al Impact of adding the immune checkpoint inhibitor atezolizumab to first-line
chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A
retrospective analysis from the IMagyn050 trial.
Gynecol Oncol. 2025;197:66-73. PubMedAbstract available
FITZGERALD KJ, Konstantinopoulos P, Matulonis U, Liu J, et al A phase I clinical trial of radiation therapy, durvalumab and tremelimumab in
recurrent gynecologic cancer.
Gynecol Oncol. 2025;197:51-56. PubMedAbstract available
LEON-CASTILLO A, Horeweg N, Peters EEM, Ter Haar N, et al Pattern of recurrence of the molecular subgroups in stage I high-grade
endometrial cancer.
Gynecol Oncol. 2025;197:43-50. PubMedAbstract available
XIE J, Maguire FB, Hofer BM, Cooley JJP, et al Disparities in hysterectomy-corrected endometrial cancer incidence trends by
histologic subtype among racial/ethnic groups in California, 2012-2019.
Gynecol Oncol. 2025;197:34-42. PubMedAbstract available
FRIEDMAN EL, Guo XM, Furey KB, Lee AJ, et al Temporal trends of sentinel lymph node biopsy without lymphadenectomy at cervical
cancer surgery.
Gynecol Oncol. 2025;196:182-191. PubMedAbstract available
GRCEVICH L, Chuzhyk O, Giannini A, McGree ME, et al Safety and feasibility of same day discharge for robotic hysterectomy and staging
for endometrial cancer.
Gynecol Oncol. 2025;197:19-24. PubMedAbstract available
WILKE RN, Wu CF, Kanbergs A, Bercow AS, et al Disparities in facility-level adoption of minimally invasive interval debulking
surgery for advanced ovarian cancer.
Gynecol Oncol. 2025;197:11-18. PubMedAbstract available
RIOS-DORIA E, Parker EU, Kohrn BF, Pike M, et al TP53 somatic evolution in the normal endometrium of Black and White individuals.
Gynecol Oncol. 2025;197:1-10. PubMedAbstract available
MORRIS DH, Kosmacki A, Tolby L, Marx C, et al Integration of a lifestyle modification intervention for women with overweight
and obesity in a gynecologic oncology practice.
Gynecol Oncol. 2025;196:168-174. PubMedAbstract available
BORCINOVA M, Kohler C, Nemejcova K, Zapardiel I, et al Preoperative tumour size assessment in patients with early-stage cervical cancer:
Final results of the SENTIX study.
Gynecol Oncol. 2025;196:160-167. PubMedAbstract available
RAIMONDO D, Raffone A, Maletta M, Restaino S, et al Hysterectomy or not for borderline ovarian tumor in menopause?
Gynecol Oncol. 2025;196:152-159. PubMedAbstract available
ZELISSE HS, Snijders MLH, Groenendijk FH, Halfwerk JBG, et al The prognostic potential of molecular subtypes including estrogen receptor status
in endometrioid ovarian cancer.
Gynecol Oncol. 2025;196:137-145. PubMedAbstract available
METTALA T, Joutsiniemi T, Huvila J, Hietanen S, et al Genetic predictors of unexpected recurrence in low-risk endometrial cancer: A
comprehensive genomic analysis reveals FGFR2 as a risk factor and a rare fatal
POLE-mutated recurrence.
Gynecol Oncol. 2025;196:129-136. PubMedAbstract available
HABLASE R, Steinke J, Aslam A, Jose R, et al Anastomotic leakage in colorectal and ovarian cancer resections: A comparative
cohort study.
Gynecol Oncol. 2025;196:121-128. PubMedAbstract available
GONZALEZ-BOSQUET J, Shahi M, Yadav S, Kanwar N, et al ECPPF stratification identifies occult high-risk subgroups in stage I, grade 1 or
2, =50 % invasive endometrial cancer: Candidates for adjuvant therapy.
Gynecol Oncol. 2025;196:113-120. PubMedAbstract available
COSGROVE CM, Suarez AA, Haight PJ, Villacres A, et al Exploring endometrial cancer risk stratification by copy number assessment.
Gynecol Oncol. 2025;196:99-106. PubMedAbstract available
KAHN RM, Murphy K, Patel T, Yeoshoua E, et al Three-dimensional volumetric rendering on augmented reality headsets for ovarian
cancer cytoreduction planning: A Memorial Sloan Kettering Cancer Center Team
Ovary study.
Gynecol Oncol. 2025;196:107-112. PubMedAbstract available
VARGIU V, Santullo F, Scambia G, Naldini A, et al STOMA study SToma-leak ratio in advanced ovarian cancer surgery: Results of a
restrictive policy on the use of protective stoMAs.
Gynecol Oncol. 2025;196:92-98. PubMedAbstract available
BUJNAK AC, Greenberg D, Chang J, Tseng J, et al Adjuvant treatment in stage I clear cell endometrial carcinoma: A
population-based study of survival outcomes.
Gynecol Oncol. 2025;196:85-91. PubMedAbstract available
WOLF B, Trantaki DS, Horn LC, Aktas B, et al Preoperative conization in cervical cancer patients undergoing open abdominal
radical hysterectomy: Results from a propensity-score matched study.
Gynecol Oncol. 2025;196:69-77. PubMedAbstract available
WESTRICK AC, Bailey Z, Schlumbrecht M Influence of residential segregation and health provider density on advanced
stage endometrial cancer diagnoses.
Gynecol Oncol. 2025;196:62-68. PubMedAbstract available
HAGHIGHAT R, Ozarowski AL, Liu YL, Frey MK, et al MUTYH: Possibly another important gene in ovarian cancer?
Gynecol Oncol. 2025;196:59-61. PubMed
CIOFFI R, Fruscio R, Sabetta G, Bergamini A, et al Consolidation courses in low-risk gestational trophoblastic neoplasia and relapse
rate: A MITO-9 retrospective study.
Gynecol Oncol. 2025;196:54-58. PubMedAbstract available
CHAM S, Kumar A, Walter LC, Lichtman S, et al Understanding frailty and the role of patient-centered care for older adults with
gynecologic cancer.
Gynecol Oncol. 2025;196:42-53. PubMedAbstract available
TA QD, Do C, Sharma K, Sorooshian HZ, et al Reduced dosing of lenvatinib with pembrolizumab for advanced endometrial cancer.
Gynecol Oncol. 2025;196:36-41. PubMedAbstract available
LEATH CA 3RD, Deng W, Mell LK, Richardson DL, et al Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally
advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III
randomized trial.
Gynecol Oncol. 2025;195:122-133. PubMedAbstract available
BRINK GJ, Groeneweg JW, van der Ploeg P, Jonges GN, et al Signal transduction pathway activity in adult-type granulosa cell tumor samples.
Gynecol Oncol. 2025;195:6-11. PubMedAbstract available
PODDER V, Slomovitz BM Rethinking metformin in advanced endometrial cancer: Scientific humility,
translational challenges, and the urgency for equity.
Gynecol Oncol. 2025;195:A1-A2. PubMed
March 2025
LORUSSO D, Oaknin A, Borges GS, Damian F, et al Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2
clinical trial.
Gynecol Oncol. 2025;196:28-35. PubMedAbstract available
XIE H, Sun L, Yao S, Tian X, et al Therapeutically targeting endometrial cancer in preclinical models by ICAM1
antibody-drug conjugates.
Gynecol Oncol. 2025;196:16-27. PubMedAbstract available
KIM J, Jang J, Lim MC, Kim MH, et al Which factors predict the effectiveness of adjuvant treatment in patients with
non-high-risk early-stage cervical cancer? Ancillary analysis of KGOG-1028.
Gynecol Oncol. 2025;196:10-15. PubMedAbstract available
MATULONIS UA, Herrstedt J, Oza A, Mahner S, et al ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and
long-term safety.
Gynecol Oncol. 2025;195:192-199. PubMedAbstract available
BUJNAK AC, Solaru SA, Tewari K Clinical applications of antibody drug conjugates for gynecologic malignancies:
Review of available medicines and emerging therapeutics.
Gynecol Oncol. 2025;195:180-191. PubMedAbstract available
ETHIER JL, Shephard C, Granados DP, Dutta N, et al Comparative efficacy and safety of low-dose versus high-dose bevacizumab in
ovarian cancer: An indirect treatment comparison.
Gynecol Oncol. 2025;196:1-9. PubMedAbstract available
JOHANNET P, Flint M, Chui MH, Konner J, et al Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1
antibody-drug conjugate.
Gynecol Oncol. 2025;195:173-179. PubMedAbstract available
LI Y, Wu M, Liu Q, Huang C, et al Development and validation of an ovarian cancer risk assessment tool for
first-degree relatives of patients in the Chinese population.
Gynecol Oncol. 2025;195:165-172. PubMedAbstract available
LEE EK, Kolin DL, Matulonis UA, Erickson BK, et al Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic
cancers.
Gynecol Oncol. 2025;195:152-164. PubMedAbstract available
DEMARI JA, Glassman D, Smith S, Darby JP, et al Endometrial cancer somatic testing practice patterns among gynecologic
oncologists.
Gynecol Oncol. 2025;195:149-151. PubMed
SULLIVAN MW, Chui MH, Selenica P, Long Roche K, et al Anaplastic carcinoma of the ovary: A single-institution experience and molecular
analysis.
Gynecol Oncol. 2025;195:144-148. PubMedAbstract available
DE BONDT D, Naslazi E, Jansen E, Kupets R, et al Validating the predicted impact of HPV vaccination on HPV prevalence, cervical
lesions, and cervical cancer: A systematic review of population level data and
modelling studies.
Gynecol Oncol. 2025;195:134-143. PubMedAbstract available
CARUSO G, Kumar A, Langstraat CL, McGree ME, et al Racial/ethnic, socioeconomic, and healthcare access disparities in achieving
textbook oncologic outcome in advanced ovarian cancer.
Gynecol Oncol. 2025;195:106-114. PubMedAbstract available
SALINARO J, Singh K, Sands N, Gill V, et al Distribution and concordance of HER2 scores in endometrial and ovarian cancer.
Gynecol Oncol. 2025;195:115-121. PubMedAbstract available
ENGH A, Rueegg CS, Bjerre Trent PK, Opheim LO, et al Physical activity and lower extremity lymphedema among endometrial cancer
survivors: A population-based cross-sectional study.
Gynecol Oncol. 2025;195:82-88. PubMedAbstract available
LINDEMANN K, Siegenthaler F, Lande KT, Casas-Arozamena C, et al Prognostic value of assessing ctDNA in patients with endometrial carcinoma - an
international multicenter study.
Gynecol Oncol. 2025;195:98-105. PubMedAbstract available
ZAMMARRELLI WA 3RD, Nandakumar S, Kertowidjojo E, Nguyen B, et al The genomic landscape of distant metastatic endometrial cancer.
Gynecol Oncol. 2025;195:89-97. PubMedAbstract available
TYAN K, Liu KX, Smart AC, Feltmate CM, et al Role of adjuvant radiotherapy modality on clinical outcomes for early-stage
uterine carcinosarcoma.
Gynecol Oncol. 2025;195:75-81. PubMedAbstract available
CARTER J, Huang HQ, Monk BJ, Kim YB, et al Evaluation of physical function and quality of life before and after nonradical
surgical therapy for stage IA1 and IA2-IB1 cervical cancer (GOG-0278).
Gynecol Oncol. 2025;195:50-58. PubMedAbstract available
BAE-JUMP VL, Sill MW, Gehrig PA, Merker JD, et al A randomized phase II/III study of paclitaxel/carboplatin/metformin versus
paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or
IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study.
Gynecol Oncol. 2025;195:66-74. PubMedAbstract available
COVENS A, Huang HQ, Monk BJ, Kim YB, et al Evaluation of efficacy and fertility after nonradical surgical therapy (extra
fascial hysterectomy or cone biopsy, with pelvic lymphadenectomy) for stage IA1,
IA2, and IB1 cervical cancer (GOG-0278).
Gynecol Oncol. 2025;195:59-65. PubMedAbstract available
LA TORRE F, Hurni Y, Farsi E, Nardi E, et al Adenomyosis associated with endometrial cancer: Possible correlation with
pathological, immunohistochemical and molecular characteristics.
Gynecol Oncol. 2025;195:45-49. PubMedAbstract available
LI X, Wang Z, Man X, Dai X, et al Research advances CRISPR gene editing technology generated models in the study of
epithelial ovarian carcinoma.
Gynecol Oncol. 2025;195:34-44. PubMedAbstract available
HICKS A, Borho L, Elishaev E, Berger J, et al All-cause mortality and neighborhood social vulnerability among women with
ovarian cancer.
Gynecol Oncol. 2025;195:26-33. PubMedAbstract available
MARCHETTI C, Ergasti R, Capomacchia FM, Giannarelli D, et al Integrating clinical-molecular data to predict PARP inhibitors efficacy in
advanced ovarian cancer patients after interval cytoreductive surgery.
Gynecol Oncol. 2025;195:16-25. PubMedAbstract available
FUCA G, Dell'Acqua C, Peruffo B, Lalli G, et al WRN dependency in dMMR/MSI-H endometrial cancer: Clinical perspectives of a novel
synthetic lethality strategy.
Gynecol Oncol. 2025;195:12-15. PubMed
DINKINS KG, Lee GM, Arend RC, Leath CA 3rd, et al Trends in FDA approvals of gynecologic oncology therapeutics from 2019 to 2024.
Gynecol Oncol. 2025;194:153-158. PubMedAbstract available
HERZOG TJ, Liao JB, Finkelstein K, Willmott L, et al An open-label randomized active-controlled phase II clinical study to assess the
efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients
with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044).
Gynecol Oncol. 2025;194:145-152. PubMedAbstract available
WENZEL L, McKinney C, Jensen S, Peipert D, et al Ensuring relevance and equity in patient reported outcomes (PROs) in endometrial
cancer: The SGO promote study (Patient Reported Outcomes Measurement
Opportunities Through Equity).
Gynecol Oncol. 2025;194:137-144. PubMedAbstract available
VELASQUEZ J, Mohammed-Norgan M, Scheiber A, Chalif J, et al Cross-language insights: Comparing Spanish and English-language cervical cancer
content on TikTok.
Gynecol Oncol. 2025;194:131-136. PubMedAbstract available
LI J, Welte T, Calzoncinth K, Vuttaradhi VK, et al An inducible FOXL2-dependent mouse model of ovarian adult type granulosa cell
tumor.
Gynecol Oncol. 2025;194:125-130. PubMedAbstract available
DEBBICHE I, Wang CC, Gomez-Roas M, Foley OW, et al Rest assured: High sleep efficiency reduces postoperative complications and
opioid prescriptions in patients undergoing surgeries with gynecologic
oncologists.
Gynecol Oncol. 2025;194:119-124. PubMedAbstract available
VAN VELZEN AF, Tulling AJ, van Poelgeest MIE, Bosse T, et al Predicting lymph node metastases in three different vulvar squamous cell
carcinoma subgroups.
Gynecol Oncol. 2025;194:86-90. PubMedAbstract available
ZANNONI GF, Angelico G, Spadola S, Bragantini E, et al Chemotherapy Response Score (CRS): A comprehensive review of its prognostic and
predictive value in High-Grade Serous Carcinoma (HGSC).
Gynecol Oncol. 2025;194:1-10. PubMedAbstract available
ESKANDER RN Implications of the platinum-free interval in endometrial cancer: A legacy worth
leaving behind?
Gynecol Oncol. 2025;194:A3-A4. PubMed
February 2025
WALKER AR, Leite S, Chen YS, Huepenbecker SP, et al Sentinel lymph node biopsy at the time of hysterectomy for early-stage cervical
cancer: A cost-effectiveness analysis.
Gynecol Oncol. 2025;195:1-5. PubMedAbstract available
ASARE A, Previs RA, Spinosa D, Fellman B, et al Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in
patients with ovarian, fallopian tube, and peritoneal cancer after progression.
Gynecol Oncol. 2025;194:112-118. PubMedAbstract available
HAIGHT PJ, Sanchez M, Thomas SM, Smitherman C, et al Platinum-free interval and response to platinum retreatment or
lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A
real-world endometrial cancer molecularly targeted therapy consortium cohort
study.
Gynecol Oncol. 2025;194:98-104. PubMedAbstract available
NOLIN AC, Atkins SL, Myers ER, Wentzensen N, et al Ultrasound-based versus immediate biopsy-based management of postmenopausal
bleeding in non-Hispanic Black and non-Hispanic White individuals.
Gynecol Oncol. 2025;194:105-111. PubMedAbstract available
MACDUFFIE E, Kernell C, George J, Bvochora-Nsingo M, et al Efficacy of induction chemotherapy during the COVID-19 pandemic for treatment of
locally advanced cervical cancer in Botswana.
Gynecol Oncol. 2025;194:91-97. PubMedAbstract available
HAIGHT P, Bilbe C, Riedinger C, Backes F, et al Defining "enlarged" sentinel lymph nodes in the setting of endometrial cancer:
What is the size cut-off?
Gynecol Oncol. 2025;194:80-85. PubMedAbstract available
ALVERO AB, Wu S, Farrell A, Kim S, et al Exploring the differences between BRCA mutated and HRwild-type high grade serous
ovarian cancer: A multiomic analysis.
Gynecol Oncol. 2025;194:71-79. PubMedAbstract available
SUN H, Huo X, Bi X, Cao D, et al Exosome transmit the ability of migration and invasion in heterogeneous ovarian
cancer cells by regulating autophagy via targeting hsa-miR-328.
Gynecol Oncol. 2025;194:60-70. PubMedAbstract available
MATSUO K, Agarwal J, Chen L, Furey KB, et al Histology-specific prognostic significance of isolated tumor cells,
micrometastases, and macrometastases in endometrial cancer.
Gynecol Oncol. 2025;194:51-59. PubMedAbstract available
TUBRIDY EA, Campbell A, Mulugeta-Gordon L, Andriani L, et al Impact of telehealth legislation on gynecologic oncology services: Policy
updates.
Gynecol Oncol. 2025;194:48-50. PubMed
GAILLARD S, Verma N, Berg M, Harrison J, et al A clinical study of tremelimumab, alone or in combination with olaparib, for
recurrent epithelial ovarian cancer.
Gynecol Oncol. 2025;194:41-47. PubMedAbstract available
CORTES-SALGADO A, Moreno-Moreno E, Carretero-Barrio I, Caniego-Casas T, et al HER2 expression in a molecularly defined cohort of endometrial cancer patients:
The SPECTRUM study.
Gynecol Oncol. 2025;194:33-40. PubMedAbstract available
KIM J, Park SY, Kim JH, Lee SW, et al Real-world efficacy and toxicity of olaparib maintenance therapy in Korean
ovarian cancer patients with an exploratory analysis of BRCA mutations.
Gynecol Oncol. 2025;194:25-32. PubMedAbstract available
ROMERO IL, Lengyel E, Wahner Hendrickson AE, Rodriguez GC, et al Metformin for patients with advanced stage ovarian cancer: A randomized phase II
placebo-controlled trial.
Gynecol Oncol. 2025;194:18-24. PubMedAbstract available
VALENZA C, Mongillo M, Visconti MV, Katrini J, et al Rechallenge with platinum-based chemotherapy in patients with platinum-resistant
ovarian carcinoma: A cohort study.
Gynecol Oncol. 2025;194:11-17. PubMedAbstract available
CORVIGNO S, Fernebro J, Karlsson JS, Mezheieusky A, et al High prevalence of FAP+ cancer-associated fibroblasts predicts poor outcome in
patients with high-grade serous ovarian cancer with high CD8 T-cell density.
Gynecol Oncol. 2025;193:148-155. PubMedAbstract available
STUEBS FA, Knoll A, Hartmann A, Leikauf LS, et al PD-L1-Expression in primary and recurrent vulvar squamous cell cancer.
Gynecol Oncol. 2025;193:98-104. PubMedAbstract available
HOROWITZ NS, St Laurent JD, Berkowitz RS Prevention of gestational trophoblastic neoplasia with actinomycin -D at the time
of evacuation: A matter of routine practice or reserve for special circumstances?
Gynecol Oncol. 2025;193:A1-A2. PubMed
January 2025
MAKI PM, Rubin LH, Krejany EO, Brand A, et al What happens after menopause? (WHAM): A prospective controlled study of cognition
24 months after premenopausal risk-reducing salpingo-oophorectomy.
Gynecol Oncol. 2025;193:141-147. PubMedAbstract available
KIM YJ, Lee J, Park S, Kim YM, et al The value of magnetic resonance imaging in predicting vesicovaginal fistula in
cervical cancer with bladder invasion treated with definitive chemoradiotherapy.
Gynecol Oncol. 2025;193:136-140. PubMedAbstract available
CLEMENTS A, Enserro D, Strickland KC, Previs R, et al Molecular classification of endometrial cancers (EC) and association with
relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary
analysis of GOG-0258.
Gynecol Oncol. 2025;193:119-129. PubMedAbstract available
O'MALLEY DM, Bariani GM, Cassier PA, Marabelle A, et al Pembrolizumab in microsatellite instability-high/mismatch repair deficient
(MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2
KEYNOTE-158 study results.
Gynecol Oncol. 2025;193:130-135. PubMedAbstract available
TOBONI MD, Dinkins K, Wu S, Mattox T, et al Not all uterine carcinosarcomas are created equal: Survival outcomes according to
molecular characterization of uterine carcinosarcoma.
Gynecol Oncol. 2025;193:89-97. PubMedAbstract available
SCHAAFSMA M, Schuurman TN, Siebers AG, Bekkers RLM, et al Cost-effectiveness of an additional hysterectomy after initially conservative
treatment for cervical adenocarcinoma in situ.
Gynecol Oncol. 2025;193:113-118. PubMedAbstract available
UBERTI EMH, de Freitas Medeiros LR, Cardoso RB, Muller KP, et al Primary prevention of post-molar gestational trophoblastic neoplasia in high-risk
complete hydatidiform mole: A single-dose prophylactic actinomycin D, associated
with uterine evacuation - a long retrospective cohort study.
Gynecol Oncol. 2025;193:105-112. PubMedAbstract available
DE VITIS LA, Reyes-Baez FE, Schivardi G, Shahi M, et al Cervical stromal invasion and molecular characterization in stage II-IV
endometrial cancers.
Gynecol Oncol. 2025;193:81-88. PubMedAbstract available
WANG H, Zhu J, Zou D, Rao Q, et al Multicenter study of ovarian cancer score for diagnosing ovarian cancer.
Gynecol Oncol. 2025;193:58-64. PubMedAbstract available
AHMED J, Stephen B, Khawaja MR, Yang Y, et al A phase I study of temsirolimus in combination with metformin in patients with
advanced or recurrent endometrial cancer.
Gynecol Oncol. 2025;193:73-80. PubMedAbstract available
MIRZA HB, Hunt A, Ennis DP, McDermott J, et al Spatial transcriptomic analysis reveals significant differences in tumor
microenvironment in HPV-dependent and HPV-independent vulvar squamous cell
carcinoma.
Gynecol Oncol. 2025;193:65-72. PubMedAbstract available
LEIJTENS L, Piek J, Verrijssen AS, Rijkaart D, et al Thromboprophylaxis in patients with locally advanced cervical cancer treated with
chemoradiation and brachytherapy.
Gynecol Oncol. 2025;193:41-48. PubMedAbstract available
RICCIUTI J, Liu Q, Khan ANMNH, Joseph JM, et al Prognostic significance of serum complement activation, neutrophil extracellular
traps and extracellular DNA in newly diagnosed epithelial ovarian cancer.
Gynecol Oncol. 2025;193:49-57. PubMedAbstract available
BOGANI G, Moore KN, Ray-Coquard I, Lorusso D, et al Incorporating immune checkpoint inhibitors in epithelial ovarian cancer.
Gynecol Oncol. 2025;193:30-40. PubMedAbstract available
WALKER AR, Leite S, Taylor N, Graul A, et al Lymph node assessment at the time of robotic hysterectomy for endometrial
intraepithelial neoplasia: A cost-effectiveness analysis.
Gynecol Oncol. 2025;193:24-29. PubMedAbstract available
SIEGENTHALER F, Imboden S, Buchi C, Christe L, et al Added prognostic value of sentinel lymph node mapping in endometrial cancer to
molecular subgroups.
Gynecol Oncol. 2025;193:12-19. PubMedAbstract available
VOSS FO, Fons G, Bruggink AH, Wenzel HHB, et al Prevalence and impact of vulvar lesions diagnosed prior to vulvar squamous cell
carcinoma: A population-based cohort study.
Gynecol Oncol. 2025;192:163-170. PubMedAbstract available
MARINO G, Marchetta L, Negri S, Testa F, et al Oncologic and fertility outcomes in patients with juvenile granulosa cell tumor -
a retrospective single centre analysis.
Gynecol Oncol. 2025;192:89-93. PubMedAbstract available
December 2024
NEILSON A, Jamieson A, Chiu D, Leung S, et al Serum CA125 levels in the context of ProMisE molecular classification provides
pre-operative prognostic information that can direct endometrial cancer
management.
Gynecol Oncol. 2024;193:1-11. PubMedAbstract available
MADDY BP, Tischer KM, McGree ME, Fought AJ, et al Implementation of enhanced recovery protocol did not increase rates of acute
kidney injury in open gynecologic oncology surgery: A single-institution
experience.
Gynecol Oncol. 2024;192:181-188. PubMedAbstract available
VOS JAM, Vos MC, van Lonkhuijzen LRCW, van de Poll-Franse LV, et al Less is more: The benefits of reduced follow-up in gynecologic cancers.
Gynecol Oncol. 2024;192:178-180. PubMed
LIU YL, Praiss AM, Chiang S, Devereaux K, et al Gestational trophoblastic neoplasm: Patient outcomes and clinical pearls from a
multidisciplinary referral center.
Gynecol Oncol. 2024;192:171-177. PubMedAbstract available
KONUMA M, Ikeda T, Mitoma T, Shirakawa S, et al Effectiveness of exercise therapy on chemotherapy-induced peripheral neuropathy
in patients with ovarian cancer: A scoping review.
Gynecol Oncol. 2024;192:155-162. PubMedAbstract available
AZAIS H, Brochard C, Taly V, Benoit L, et al Prognostic value of circulating tumor DNA at diagnosis and its early decrease
after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial
ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial.
Gynecol Oncol. 2024;192:145-154. PubMedAbstract available
NGUYEN T, Yi Y, Morron S, Brittain D, et al Living in a food desert in Louisiana and its effects on gynecologic cancer
outcomes.
Gynecol Oncol. 2024;192:137-144. PubMedAbstract available
MIRZA MR, Bjorge L, Marme F, Christensen RD, et al Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent
endometrial cancer: Double-blind placebo-controlled randomized phase II
ENGOT-EN3/PALEO trial.
Gynecol Oncol. 2024;192:128-136. PubMedAbstract available
GRAVES S, Sullivan MW, Adkoli A, Zhou Q, et al Association between genomic instability score and progression-free/overall
survival in patients with newly diagnosed non-BRCA1/2 ovarian cancer.
Gynecol Oncol. 2024;192:120-127. PubMedAbstract available
CASTELLANO T, Lara OD, McCormick C, Chase D, et al Clinical trial screening in gynecologic oncology: Defining the need and
identifying best practices.
Gynecol Oncol. 2024;192:111-119. PubMedAbstract available
PREVIS RA, Strickland KC, Wallen Z, Ko H, et al Analysis of real world FRalpha testing in ovarian, fallopian tube, and primary
peritoneal cancers.
Gynecol Oncol. 2024;192:102-110. PubMedAbstract available
COLSON-FEARON D, Viswanathan AN Trends in brachytherapy in utilization for vaginal cancer in the United States
from 2004 to 2021.
Gynecol Oncol. 2024;191:228-232. PubMedAbstract available
MOUFARRIJ S, Dagher C, Filippova OT, Zhou Q, et al Five-year quality-of-life assessment by urinary diversion type after pelvic
Exenterations.
Gynecol Oncol. 2024;191:212-218. PubMedAbstract available
FEDERICO A, Lancellotta V, Fragomeni SM, Macchia G, et al Surgery after upfront chemoradiation in locally advanced squamous cell vulvar
cancer: Analysis of postoperative outcomes and survival.
Gynecol Oncol. 2024;191:106-113. PubMedAbstract available
WONG TY, Adzibolosu NK, Mattei LH, Speak AC, et al Disparities in contemporary human papilloma virus vaccination uptake among adult
women living in the United States: An All of Us Research Program study.
Gynecol Oncol. 2024;191:100-105. PubMedAbstract available
THAYER EG, Manning-Geist BL Following the folate receptor: Expanding targeted treatment options in low grade
serous ovarian carcinoma.
Gynecol Oncol. 2024;191:A1-A2. PubMed
November 2024
SHU T, Liang Y, Zhang S, Sun T, et al The prognostic value of tumor-informed minimal residual disease detection using
circulating tumor DNA in first-line treatment of ovarian cancer.
Gynecol Oncol. 2024;192:94-101. PubMedAbstract available
BORHO L, Elishaev E, Bao R, O'Brien E, et al Association of neighborhood social vulnerability with ovarian cancer survival.
Gynecol Oncol. 2024;192:32-39. PubMedAbstract available
KLEPPE A, Lindemann K, Kildal W, Tobin KAR, et al Prognostic and therapeutic implication of molecular classification including
L1CAM expression in high-risk endometrial cancer.
Gynecol Oncol. 2024;192:80-88. PubMedAbstract available
CLASSEN CC, Chivers ML, Brotto LA, Barbera L, et al A randomized controlled trial of an online support group addressing psychosexual
distress among women treated for gynecologic cancer.
Gynecol Oncol. 2024;192:73-79. PubMedAbstract available
SONAVANE M, Hedlich-Dwyer J, Dal Zotto VL, Tang M, et al Repair Assisted Damage Detection (RADD) as a predictive biomarker for
immunotherapy response in ovarian cancer.
Gynecol Oncol. 2024;192:65-72. PubMedAbstract available
KHADRAOUI W, Sinnott JA, Meade CE, Plascak J, et al Clinical trial enrollment during first course of gynecologic cancer treatment and
survival.
Gynecol Oncol. 2024;192:59-64. PubMedAbstract available
MULUGETA-GORDON L, Smith AJB Insurance coverage and access to gynecologic oncology: Where are we are now.
Gynecol Oncol. 2024;192:56-58. PubMedAbstract available
FRANCIS KE, Simon S, Gebski V, Joly F, et al Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of
olaparib in recurrent ovarian cancer.
Gynecol Oncol. 2024;192:50-55. PubMedAbstract available
POWELL MA, Cibula D, O'Malley DM, Boere I, et al Efficacy and safety of dostarlimab in combination with chemotherapy in patients
with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3,
randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
Gynecol Oncol. 2024;192:40-49. PubMedAbstract available
COLEMAN RL, Lubinga SJ, Shen Q, Walder L, et al Cost-effectiveness of dostarlimab plus carboplatin-paclitaxel for primary
advanced or recurrent endometrial cancer from a US payer perspective.
Gynecol Oncol. 2024;192:24-31. PubMedAbstract available
DE JAEGHERE EA, Hamerlinck H, Tuyaerts S, Lippens L, et al Associations of the gut microbiome with outcomes in cervical and endometrial
cancer patients treated with pembrolizumab: Insights from the phase II PRIMMO
trial.
Gynecol Oncol. 2024;191:275-286. PubMedAbstract available
VREDE SW, Van Weelden WJ, Bulten J, Gilks CB, et al Hormonal biomarkers remain prognostically relevant within the molecular subgroups
in endometrial cancer.
Gynecol Oncol. 2024;192:15-23. PubMedAbstract available
MOUFARRIJ S, Lakhman Y, Aghajanian C, Abu-Rustum NR, et al Evolutionary pathways in early-stage, non-myoinvasive endometrioid endometrial
cancers of no specific molecular profile.
Gynecol Oncol. 2024;192:8-14. PubMedAbstract available
HICKEY M, Nguyen TL, Krejany EO, Domchek SM, et al What happens after menopause? (WHAM): Impact of risk-reducing
salpingo-oophorectomy on depressive and anxiety symptoms at 24 months.
Gynecol Oncol. 2024;192:1-7. PubMedAbstract available
KILOWSKI KA, Dietrich MF, Xiu J, Baca Y, et al KRAS mutations in endometrial cancers: Possible prognostic and treatment
implications.
Gynecol Oncol. 2024;191:299-306. PubMedAbstract available
LEE AW, Poynor V, Siddiqui S Disparities in ovarian cancer survival among ethnic Asian American populations,
2006-2020.
Gynecol Oncol. 2024;191:292-298. PubMedAbstract available
BOITANO TKL, Blank SV, Havrilesky LJ, Huh WK, et al Too much of a good thing? Projecting the need for gynecologic oncologists over
the next 20 years.
Gynecol Oncol. 2024;191:287-291. PubMedAbstract available
JAIN D, Zaeim F, Wahidi M, Smith WJ, et al Cervical squamous cell carcinoma outcomes across continents: A retrospective
study.
Gynecol Oncol. 2024;190:272-282. PubMedAbstract available
PROPPE L, Jaeger A, Goy Y, Petersen C, et al Systematic review - Adjuvant radiotherapy of the vulva in primary vulvar cancer.
Gynecol Oncol. 2024;190:264-271. PubMedAbstract available
CHOI YK, Lee JH, Kim YS, Wee CW, et al Mid-treatment MRI-based tumor response assessment for tumor recurrence and
patient survival in locally advanced adenocarcinoma of the cervix: A
retrospective multicenter study of KROG 23-03.
Gynecol Oncol. 2024;190:222-229. PubMedAbstract available
SHIBATA M, Yoshida K, Yokoi A, Suzuki H, et al Elucidation of the role of XBP1 in the progression of complete hydatidiform mole
to invasive mole through RNA-seq.
Gynecol Oncol. 2024;190:189-199. PubMedAbstract available
NONZEE NJ, Thiel de Bocanegra H, Navarro S, Bastani R, et al Impact of management guidelines for abnormal cervical cytology on colposcopy
procedure rates among young women.
Gynecol Oncol. 2024;190:160-166. PubMedAbstract available
HEUS C, Stelten S, Kenter GG, Buffart LM, et al Body composition and peri- and postoperative complications in patients with
gynaecological malignancies: A systematic review.
Gynecol Oncol. 2024;190:131-138. PubMedAbstract available
WEBBER JW, Wollborn L, Mishra S, Vitonis AF, et al Serum miRNA improves the accuracy of a multivariate index assay for triage of an
adnexal mass.
Gynecol Oncol. 2024;190:124-130. PubMedAbstract available
METCALF CA, Page CE, Stocker BOS, Johnson RL, et al Treating new-onset cognitive complaints after risk-reducing
salpingo-oophorectomy: A randomized controlled crossover trial of
lisdexamfetamine.
Gynecol Oncol. 2024;190:62-69. PubMedAbstract available
MERTEN R, Strnad V, Karius A, Lotter M, et al Brachytherapy in vaginal cancer for organ preservation: Clinical outcome and
safety from a single center experience.
Gynecol Oncol. 2024;190:35-41. PubMedAbstract available
TEE XR, Hazard E, Latorre-Esteves E, Kohrn BF, et al Increased TP53 somatic evolution in peritoneal washes of individuals with BRCA1
germline mutations.
Gynecol Oncol. 2024;190:18-27. PubMedAbstract available
BROWN J Hormonal maintenance therapy for advance low grade serous ovarian carcinoma
appears to be of benefit - That's a relief!
Gynecol Oncol. 2024;190:A1-A2. PubMed
October 2024
VER HOEVE ES, Rumble ME, Gorzelitz JS, Rose SL, et al Biobehavioral predictors of mood, pain, fatigue, and insomnia in endometrial
cancer survivors.
Gynecol Oncol. 2024;191:265-274. PubMedAbstract available
HUNSBERGER KS, Tewari KS, Monk BJ, Chase DM, et al Standard of care treatment for stage IVB cervical cancer: A systematic review and
meta-analysis.
Gynecol Oncol. 2024;191:259-264. PubMedAbstract available
MOORE KN, Lorusso D, Oaknin A, Oza A, et al Safety and tolerability of mirvetuximab soravtansine monotherapy for folate
receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary.
Gynecol Oncol. 2024;191:249-258. PubMedAbstract available
PENG S, Zheng Y, Liu J, Chen S, et al Molecular classification in fertility-sparing treatment of early-stage
endometrial cancer: A potential tool for optimizing patient selection.
Gynecol Oncol. 2024;191:240-248. PubMedAbstract available
GARCIA-DONAS J, Redondo A, Santaballa A, Garrigos L, et al Phase II clinical trial assessing the efficacy of enzalutamide in advanced
non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016-01).
Gynecol Oncol. 2024;191:233-239. PubMedAbstract available
NAGASE Y, Matsuo K, Nakao Y, Hisa T, et al Adjuvant therapy de-escalation for stage I uterine leiomyosarcoma: A systematic
review and meta-analysis.
Gynecol Oncol. 2024;191:219-227. PubMedAbstract available
LI G, Li X, Yin R, Feng M, et al Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with
PD-L1 positive recurrent/metastatic cervical cancer.
Gynecol Oncol. 2024;191:165-171. PubMedAbstract available
HICKEY M, Trainer AH, Krejany EO, Brand A, et al What happens after menopause? (WHAM): A prospective controlled study of vasomotor
symptoms and menopause-related quality of life 24 months after premenopausal
risk-reducing salpingo-oophorectomy (RRSO).
Gynecol Oncol. 2024;191:201-211. PubMedAbstract available
HAIGHT PJ, Lammers S, Kistenfeger Q, Leipold C, et al Cold ischemia time and formalin fixation time in endometrial cancer: Should
breast cancer guidelines for preanalytical variables be applied to hysterectomy
specimens?
Gynecol Oncol. 2024;191:194-200. PubMedAbstract available
YONEMORI K, Boni V, Min KG, Meniawy TM, et al Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and
combined with abemaciclib, in recurrent/advanced ER-positive endometrioid
endometrial cancer: Results from the phase 1a/1b EMBER study.
Gynecol Oncol. 2024;191:172-181. PubMedAbstract available
ELAYAPILLAI SP, Dogra S, Lausen J, Parker M, et al ATR inhibition increases reliance on PARP-mediated DNA repair revealing an
improved therapeutic strategy for cervical cancer.
Gynecol Oncol. 2024;191:182-193. PubMedAbstract available
PLINSINGA ML, Rye S, Jones T, Vagenas D, et al Mild symptoms matter: Results from a prospective, longitudinal study on the
relationship between symptoms, lymphedema and health-related outcomes
post-gynecological cancer.
Gynecol Oncol. 2024;191:158-164. PubMedAbstract available
PERRONE E, Capasso I, Giannarelli D, Trozzi R, et al Less is more? Comparison between genomic profiling and immunohistochemistry-based
models in endometrial cancer molecular classification: A multicenter,
retrospective, propensity-matched survival analysis.
Gynecol Oncol. 2024;191:150-157. PubMedAbstract available
OGASAWARA A, Matsushita H, Tan TZ, Shintani D, et al Immunological impact of intraperitoneal and intravenous chemotherapy in ovarian
cancer, translational analyses of the Phase 3 iPocc trial.
Gynecol Oncol. 2024;191:124-131. PubMedAbstract available
SAAB R, Fellman BM, Legarreta AF, Meyer LA, et al Comparative analysis of hormonal therapy in low-grade endometrial stromal
sarcoma: A retrospective study.
Gynecol Oncol. 2024;191:143-149. PubMedAbstract available
PINTO P, Moro F, Alcazar JL, Alessi S, et al Prediction of non-resectability in tubo-ovarian cancer patients using Peritoneal
Cancer Index - A prospective multicentric study using imaging (ISAAC study).
Gynecol Oncol. 2024;191:132-142. PubMedAbstract available
KONG W, Deng B, Shen X, John C, et al Tirzepatide as an innovative treatment strategy in a pre-clinical model of
obesity-driven endometrial cancer.
Gynecol Oncol. 2024;191:116-123. PubMedAbstract available
NG ZY, Manchanda R, Lopez A, Obermair A, et al The prognosis of stage IA cervical cancer: Subgroup analysis of the SCCAN study.
Gynecol Oncol. 2024;191:95-99. PubMedAbstract available
CARUSO G, Langstraat CL, Kumar A, McGree ME, et al Textbook oncologic outcome is an easy-to-use composite quality measure that is
strongly associated with survival in advanced-stage ovarian cancer.
Gynecol Oncol. 2024;191:86-94. PubMedAbstract available
RUSHTON T, Krause HB, Samec T, Elliott A, et al Characterizing the genomic landscape through the lens of FOLR1 status in low and
high grade serous ovarian carcinoma.
Gynecol Oncol. 2024;191:80-85. PubMedAbstract available
LIAO JB, Jejurikar NS, Hitchcock-Bernhardt KM, Gwin WR, et al Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent
refractory ovarian cancer.
Gynecol Oncol. 2024;191:74-79. PubMedAbstract available
BRITTON MC, Izampuye E, Clark M, Ornstein RA, et al Diagnostic experiences of Black and White patients with uterine cancer: A
qualitative study.
Gynecol Oncol. 2024;191:67-73. PubMedAbstract available
VAZ J, Piver R, Brzezinska B, Suhner J, et al Nutrition's checkpoint inhibition: The impact of nutrition on immunotherapy
outcomes.
Gynecol Oncol. 2024;189:129-136. PubMedAbstract available
September 2024
WAN S, Gao Y, Wu S, Wang H, et al Somatic mutation of targeted sequencing identifies risk stratification in
advanced ovarian clear cell carcinoma.
Gynecol Oncol. 2024;191:56-66. PubMedAbstract available
LINDQUIST S, Kjaer SK, Frederiksen K, Ornskov D, et al Comparative analysis of HPV testing versus cytology in Danish cervical cancer
screening: Insights from a large-scale implementation study.
Gynecol Oncol. 2024;191:45-55. PubMedAbstract available
PRAISS AM, Dagher C, Zhou Q, Iasonos A, et al Lymph node metastases in endometrial carcinoma: A modern assessment in the era of
sentinel lymph node mapping and molecular subtyping.
Gynecol Oncol. 2024;191:37-44. PubMedAbstract available
YANG X, Li C, Li Z, Du D, et al The clinical value of ultrasound-guided sacral anesthesia in Intracavitary and/or
interstitial brachytherapy for cervical Cancer.
Gynecol Oncol. 2024;191:31-36. PubMedAbstract available
LI X, Argenta PA, Brown K, Honeyfield K, et al Associations of cytomegalovirus infection with cancer-related cognitive
impairment and peripheral neuropathy in ovarian cancer survivors.
Gynecol Oncol. 2024;191:25-30. PubMedAbstract available
JANG EB, Lee AJ, So KA, Lee SJ, et al Risk factors for the recurrence in patients with early endometrioid endometrial
cancer achieving complete remission for fertility-sparing hormonal treatment.
Gynecol Oncol. 2024;191:19-24. PubMedAbstract available
ANASTASIO MK, Nolin A, Penvose KN, Lambert K, et al Adjuvant therapy and recurrence risk in non-myoinvasive high-grade (stage IC)
endometrial cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2024;191:10-18. PubMedAbstract available
NIEF CA, Long SE, McCleary TL, Kidd E, et al Diabetes mellitus complications associated with recurrence of stage I
endometrioid endometrial cancer: A single-center retrospective study.
Gynecol Oncol. 2024;190:298-306. PubMedAbstract available
MOUFARRIJ S, Gazzo A, Rana S, Selenica P, et al Concurrent POLE hotspot mutations and mismatch repair deficiency/microsatellite
instability in endometrial cancer: A challenge in molecular classification.
Gynecol Oncol. 2024;191:1-9. PubMedAbstract available
FULLERTON R, Martell K, Khanolkar R, Phan T, et al Impact of immune, inflammatory and nutritional indices on outcome in patients
with locally advanced cervical cancer treated with definitive
(chemo)radiotherapy.
Gynecol Oncol. 2024;190:291-297. PubMedAbstract available
BROWN J, Miller A, Holman LL, Backes F, et al Results of a randomized phase II trial of paclitaxel and carboplatin versus
bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive
stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14.
Gynecol Oncol. 2024;190:283-290. PubMedAbstract available
NAHSHON C, Leitao MM Jr, Segev Y Response to the letter to the editor: Referring to the manuscript entitled
"Surgical nodal assessment for endometrial hyperplasia - A meta-analysis and
systematic review".
Gynecol Oncol. 2024;190:262-263. PubMed
ADJEI NN, Haas A, Zhao H, Primm KM, et al Real-world trends in the use of maintenance therapy in ovarian cancer across the
United States from 2017 to 2021.
Gynecol Oncol. 2024;190:255-261. PubMedAbstract available
NGUYEN L, Chung TH, Le YL, Reygaerts H, et al Hispanic individuals' cervical cancer screening disparities amidst the COVID-19
pandemic.
Gynecol Oncol. 2024;190:243-249. PubMedAbstract available
RIOS-DORIA E, Nobre SP, Sassine D, Glaser G, et al Impact of adjuvant therapy on oncologic outcomes in uterine-confined clear cell
carcinoma of the endometrium.
Gynecol Oncol. 2024;190:236-242. PubMedAbstract available
MOKSHAGUNDAM S, McGree ME, Tapia AL, Fought AJ, et al Physical and psychological distress amongst patients undergoing neoadjuvant
chemotherapy for advanced ovarian cancer.
Gynecol Oncol. 2024;190:230-235. PubMedAbstract available
YOUNG AN, Lin LH, Abel MK, Badhey MO, et al Atypical placental site nodules: Clinicopathologic features, management and
patient outcomes in an institutional series.
Gynecol Oncol. 2024;190:215-221. PubMedAbstract available
POTHURI B, Sawaged Z, Karpel HC, Li X, et al A phase 2 feasibility study of nab-paclitaxel and carboplatin in epithelial
carcinoma of the uterus.
Gynecol Oncol. 2024;190:209-214. PubMedAbstract available
PIFER PM, Kilar CR, Beriwal S Is substantial lymphovascular space invasion in FIGO stage I endometrial
carcinoma ready for primetime in deciding adjuvant treatment?
Gynecol Oncol. 2024;188:A1-A3. PubMed
WALL JA, Pozzar RA, Enzinger AC, Tavormina A, et al Improving the palliative-procedure decision-making process for patients with
peritoneal carcinomatosis: A secondary analysis.
Gynecol Oncol. 2024;188:125-130. PubMedAbstract available
WILKE RN, Iniesta MD, Fellman B, Jazaeri AA, et al A colostomy for large bowel obstruction at the end of life: What do patients gain
from palliative surgery?
Gynecol Oncol. 2024;188:120-124. PubMedAbstract available
MONK BJ, Tewari KS, Randall LM, Pothuri B, et al Immunotherapy in locally advanced cervix cancer: A critical appraisal of the FDA
indication based on ENGOT-CX11/GOG-3047/KEYNOTE-A18.
Gynecol Oncol. 2024;188:81-82. PubMed
LAMBERT KA, Albright BB, Anastasio MK, Kaplan SJ, et al Scalp hypothermia to reduce chemotherapy-induced alopecia: A systematic review
and meta-analysis.
Gynecol Oncol. 2024;188:71-80. PubMedAbstract available
WILHITE AM, Wu S, Xiu J, Gibney GT, et al A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type
compared with cutaneous melanoma.
Gynecol Oncol. 2024;188:13-21. PubMedAbstract available
POZZAR RA, Enzinger AC, Howard C, Tavormina A, et al Feasibility and acceptability of a nurse-led telehealth intervention (BOLSTER) to
support patients with peritoneal carcinomatosis and their caregivers: A pilot
randomized clinical trial.
Gynecol Oncol. 2024;188:1-7. PubMedAbstract available
August 2024
LIM H, Kim SI, Kim MK, Yoon SH, et al Initial sarcopenia and body composition changes as prognostic factors in cervical
cancer patients treated with concurrent chemoradiation: An artificial
intelligence-based volumetric study.
Gynecol Oncol. 2024;190:200-208. PubMedAbstract available
MILLER EA, Chowdhary B, Chapman-Davis E Beyond the decision: Reproductive justice and cervical cancer care in a
post-Dobbs era.
Gynecol Oncol. 2024;190:186-188. PubMedAbstract available
MEERNIK C, Osazuwa-Peters OL, Wilson LE, Joshi A, et al Frailty in patients with ovarian cancer and the role of healthcare access, race,
and ethnicity.
Gynecol Oncol. 2024;190:146-152. PubMedAbstract available
FRICOVA L, Kommoss S, Scambia G, Ferron G, et al Reproductive outcomes after fertility-sparing surgery for cervical cancer -
results of the multicenter FERTISS study.
Gynecol Oncol. 2024;190:179-185. PubMedAbstract available
QI C, Lyu M, Yao Z, Zhang F, et al SVIL promotes ovarian cancer progression and epithelial-mesenchymal transition
under hypoxic conditions through the TGF-beta/Smad pathway.
Gynecol Oncol. 2024;190:167-178. PubMedAbstract available
CHUK E, Conway JL, Hanuschak J, Han K, et al Patient-reported sexual health outcomes of cervical cancer patients treated with
definitive chemoradiation and MRI-guided brachytherapy.
Gynecol Oncol. 2024;190:153-159. PubMedAbstract available
KATO MK, Fujii E, Yamaguchi M, Higuchi D, et al Excellent concordance of the molecular classification between preoperative biopsy
and final hysterectomy in endometrial carcinoma.
Gynecol Oncol. 2024;190:139-145. PubMedAbstract available
BARAKZAI SK, Bregar AJ, Del Carmen MG, Eisenhauer EL, et al The association of maintenance hormone therapy with overall survival in
advanced-stage low-grade serous ovarian carcinoma: A risk-set matched
retrospective study.
Gynecol Oncol. 2024;190:119-123. PubMedAbstract available
YUNOKAWA M, Kurihara N, Ishizuka N, Kanao H, et al Investigating the timing and site of recurrence for ovarian clear cell carcinoma:
Analysis of the JGOG/GCIG trial-JGOG 3017-A3.
Gynecol Oncol. 2024;190:113-118. PubMedAbstract available
SKOF E, Stegel V, Dragos VS, Blatnik A, et al Exploring the impact of BRCA1 and BRCA2 mutation type and location on Olaparib
maintenance therapy in platinum-sensitive relapsed ovarian Cancer patients: A
single center report.
Gynecol Oncol. 2024;190:104-112. PubMedAbstract available
LEMIEUX M, Telles R, Goodheart M, Dahmoush L, et al Quality of life and survivorship in patients with low-grade ovarian cancer.
Gynecol Oncol. 2024;190:96-103. PubMedAbstract available
KOTSOPOULOS J, Lubinski J, Huzarski T, Bychkovsky BL, et al Incidence of endometrial cancer in BRCA mutation carriers.
Gynecol Oncol. 2024;189:148-155. PubMedAbstract available
WAGAR MK, Patel UJ, Bharucha K, Heisler CA, et al Postoperative urinary retention by void trial methodology following radical
hysterectomy for cervical cancer.
Gynecol Oncol. 2024;190:90-95. PubMedAbstract available
GUERRA RA, Kaplan C, Borno H, Boscardin J, et al The role of race/ethnicity and age in clinical trial knowledge among patients
with gynecologic malignancy.
Gynecol Oncol. 2024;190:84-89. PubMedAbstract available
SUZUKI Y, Chen L, Matsuo K, Ferris JS, et al Weight-loss therapy in patients with obesity with endometrial intraepithelial
neoplasia and uterine cancer.
Gynecol Oncol. 2024;190:78-83. PubMedAbstract available
GAMBLE CR, Huang Y, Quinn J, Melamed A, et al Neighborhood economic vulnerability as a predictor for patterns of care and
outcomes for patients with uterine cancer.
Gynecol Oncol. 2024;190:70-77. PubMedAbstract available
ROSS TL, Na R, Au-Yeung G, DeFazio A, et al Are exercise and sitting time during chemotherapy for ovarian cancer associated
with treatment-related side-effects, chemotherapy completion and survival?
Gynecol Oncol. 2024;190:53-61. PubMedAbstract available
YOKOI A, Machida H, Shimada M, Mastuo K, et al Efficacy and safety of minimally invasive surgery versus open laparotomy for
epithelial ovarian cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2024;190:42-52. PubMedAbstract available
GU Y, Liu Y, Cheng H, Wang W, et al Clinicopathological characteristics and oncologic outcomes of patients with
gestational trophoblastic neoplasia manifesting as isolated pulmonary lesions.
Gynecol Oncol. 2024;190:28-34. PubMedAbstract available
CUN HT, Bernard L, Lande KT, Lawson BC, et al Comprehensive molecular characterization of early stage grade 3 endometrioid
endometrial adenocarcinoma.
Gynecol Oncol. 2024;189:138-145. PubMedAbstract available
FROEDING LP, Jensen PT Commentary on "Simple versus radical hysterectomy in women with low-risk cervical
cancer" by Plante M. et al. published in The New England Journal of Medicine.
Gynecol Oncol. 2024;189:137. PubMed
OSTBY SA, Narasimhulu D, Ochs Kinney MA, Cliby W, et al Defining optimal perioperative analgesia in patients undergoing laparotomy for
advanced gynecologic malignancy: A randomized controlled trial.
Gynecol Oncol. 2024;190:11-17. PubMedAbstract available
RIEDINGER CJ, Sakach J, Maples JM, Fulton J, et al Glucagon-like peptide-1 (GLP-1) receptor agonists for weight management: A review
for the gynecologic oncologist.
Gynecol Oncol. 2024;190:1-10. PubMedAbstract available
HOLTZMAN S, Gellman C, Kaplowitz E, Barber E, et al Yes, it's true: Benign hysterectomy trends for gynecologic oncologists in the
United States from 2015 to 2021.
Gynecol Oncol. 2024;189:125-128. PubMedAbstract available
CHELSEA NN, Posever N, Hsieh TYJ, Patterson S, et al Implementation of a financial navigation program in gynecologic oncology.
Gynecol Oncol. 2024;189:119-124. PubMedAbstract available
VAN DER EERDEN B, de Rooij BH, Schouten LJ, Boll D, et al Quality of life among borderline ovarian tumor survivors: A comparison with
survivors of early-stage ovarian cancer and a cancer-free population: A
cross-sectional population-based PROFILES study.
Gynecol Oncol. 2024;189:111-118. PubMedAbstract available
GLASER S, Han E Optimizing and harmonizing lymph node dissection and radiotherapy in advanced
vulvar cancer.
Gynecol Oncol. 2024;187:A1-A2. PubMed
STROOT IAS, Bart J, Hollema H, Jalving M, et al Long-term outcome of high-grade serous carcinoma established in risk-reducing
salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic
variant carriers.
Gynecol Oncol. 2024;187:198-203. PubMedAbstract available
WAGAR MK, Naik A, Zhang RC, Godecker A, et al Incidence of postoperative venous thromboembolism in patients with vulvar
carcinoma undergoing vulvectomy with or without lymphadenectomy.
Gynecol Oncol. 2024;187:192-197. PubMedAbstract available
DEL VALLE D, Ruiz R, Lekuona A, Cobas P, et al Superparamagnetic iron oxide (SPIO) for sentinel lymph node detection in vulvar
cancer.
Gynecol Oncol. 2024;187:145-150. PubMedAbstract available
VAN DEN BERG CB, Dasgupta S, Ewing-Graham PC, Bart J, et al Does serous tubal intraepithelial carcinoma (STIC) metastasize? The clonal
relationship between STIC and subsequent high-grade serous carcinoma in BRCA1/2
mutation carriers several years after risk-reducing salpingo-oophorectomy.
Gynecol Oncol. 2024;187:113-119. PubMedAbstract available
ADOLPH L, Mann A, Liu XQ, Roberts L, et al Follow-up of women with cervical adenocarcinoma in situ treated by conization: A
single centre clinical experience.
Gynecol Oncol. 2024;187:74-79. PubMedAbstract available
VUE NC, Sassani J, Prairie B, Yin Y, et al Clinical outcomes with utilization of high-potency topical steroids in patients
with lichen sclerosus-associated vulvar cancer.
Gynecol Oncol. 2024;187:58-63. PubMedAbstract available
SWIFT BE, Khoja L, Matthews J, Croke J, et al Management of inguinal lymph nodes in locally advanced, surgically unresectable,
squamous cell carcinoma of the vulva.
Gynecol Oncol. 2024;187:46-50. PubMedAbstract available
July 2024
DA COSTA AABA, Souza RP, Pandolfi NC, de Souza Castro F, et al Should we consider progression-free survival benefits enough for drug approvals
in locally advanced cervical cancer?
Gynecol Oncol. 2024;189:109-110. PubMed
JOHANSEN G, Lampic C, Floter Radestad A, Dahm-Kahler P, et al Health-related quality of life, sexual function, psychological health,
reproductive concerns and fertility outcome in young women treated with
fertility-sparing surgery for ovarian tumors - A prospective longitudinal
multicentre study.
Gynecol Oncol. 2024;189:101-108. PubMedAbstract available
ZANNONI GF, Santoro A, Arciuolo D, Travaglino A, et al Endometrial cancer and 2023 FIGO staging system: Not too soon, but maybe too
much?
Gynecol Oncol. 2024;189:98-100. PubMed
GUPTA A, O'Cearbhaill RE, Block MS, Hamilton E, et al Vaccination with folate receptor-alpha peptides in patients with ovarian cancer
following response to platinum-based therapy: A randomized, multicenter clinical
trial.
Gynecol Oncol. 2024;189:90-97. PubMedAbstract available
SULLIVAN MW, Kanbergs AN, Growdon WB Letter to the Editor: Referring to the manuscript entitled "Surgical nodal
assessment for endometrial hyperplasia - A meta-analysis and systematic review"
recently reported from Nahshon et al. (Gynecol Oncol., 188;140-146;2024).
Gynecol Oncol. 2024;189:88-89. PubMed
HUEPENBECKER SP, Soliman PT, Meyer LA, Iniesta MD, et al Perioperative outcomes in gynecologic pelvic exenteration before and after
implementation of an enhanced recovery after surgery program.
Gynecol Oncol. 2024;189:80-87. PubMedAbstract available
FINCH L, Broach V, Feinberg J, Al-Niaimi A, et al ChatGPT compared to national guidelines for management of ovarian cancer: Did
ChatGPT get it right? - A Memorial Sloan Kettering Cancer Center Team Ovary
study.
Gynecol Oncol. 2024;189:75-79. PubMedAbstract available
LEE YW, Wang V, Wang MJ, Kim KH, et al The effects of Asian American Pacific Islander (AAPI) data inequities in
gynecologic oncology.
Gynecol Oncol. 2024;189:64-67. PubMedAbstract available
KAMRAVA MR, Gonzalez-Martin A, Pothuri B, Vergote I, et al Patterns of initial ovarian cancer recurrence on niraparib maintenance
monotherapy in patients with no baseline evidence of disease after first-line
chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012.
Gynecol Oncol. 2024;189:68-74. PubMedAbstract available
CABRERA S, Bebia V, Lopez-Gil C, Luzarraga-Aznar A, et al Molecular classification improves preoperative risk assessment of endometrial
cancer.
Gynecol Oncol. 2024;189:56-63. PubMedAbstract available
BERGSTEIN A, Huang Y, Hershman DL, Xu X, et al Impact of medicaid expansion on cervical cancer screening: A state-specific
difference in difference analysis.
Gynecol Oncol. 2024;189:49-55. PubMedAbstract available
SENGUTTUVAN RN, Lugo-Santiago N, Nakamura B, Song M, et al Uterine cancer restaging according to the updated 2023 FIGO Guidelines does not
uniformly affect prognosis: An institutional retrospective cohort study.
Gynecol Oncol. 2024;189:41-48. PubMedAbstract available
POLAN RM, Ali-Fehmi R, Grace AK, Mattei LH, et al Occult residual ovarian tissue at the time of minimally invasive risk reducing
surgery in women with BRCA mutations.
Gynecol Oncol. 2024;189:37-40. PubMedAbstract available
ANDRES S, Finch L, Iasonos A, Zhou Q, et al Basket study of oral progesterone antagonist onapristone extended release in
progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian
cancer, or endometrioid endometrial cancer.
Gynecol Oncol. 2024;189:30-36. PubMedAbstract available
MAHONEY DE, Mukherjee R, Thompson J Elucidating the influences of social determinants of health on perceived overall
health among African American/Black and Hispanic ovarian cancer survivors using
the NIH All of Us Research Program.
Gynecol Oncol. 2024;189:24-29. PubMedAbstract available
MCNAMARA B, Greenman M, Bellone S, Santin LA, et al Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed
antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in
ovarian carcinoma.
Gynecol Oncol. 2024;189:16-23. PubMedAbstract available
ARO K, Pasanen A, Butzow R, Loukovaara M, et al The impact of estrogen receptor and L1 cell adhesion molecule expression on
endometrial cancer outcome correlates with clinicopathological risk group and
molecular subgroup.
Gynecol Oncol. 2024;189:9-15. PubMedAbstract available
GRAHAM O, Rodriguez J, Abbott R, Lomonosova E, et al A toolkit for a modern gynecologic oncology tissue bank.
Gynecol Oncol. 2024;189:1-8. PubMedAbstract available
EZENDAM NPM, de Rooij BH, Creutzberg CL, Kruitwagen RFPM, et al Effect of reduced follow-up care on patient satisfaction with care among patients
with endometrial cancer: The ENSURE randomized controlled trial.
Gynecol Oncol. 2024;188:169-183. PubMedAbstract available
KUMAR PP, Smith D, Key J, Dong H, et al Preclinical 3D model screening reveals digoxin as an effective therapy for a rare
and aggressive type of endometrial cancer.
Gynecol Oncol. 2024;188:162-168. PubMedAbstract available
SHALOWITZ DI, Rajczi A Refining research on access to gynecologic cancer care: The DIMeS framework.
Gynecol Oncol. 2024;188:158-161. PubMedAbstract available
CROWLEY F, Broderick S, Francis JH, O'Cearbhaill RE, et al Ocular side effects of anticancer agents used in the treatment of gynecologic
cancers.
Gynecol Oncol. 2024;188:147-157. PubMedAbstract available
NAHSHON C, Leitao MM Jr, Lavie O, Schmidt M, et al Surgical nodal assessment for endometrial hyperplasia - A meta-analysis and
systematic review.
Gynecol Oncol. 2024;188:140-146. PubMedAbstract available
STEWART KT, Jafari H, Pattillo J, Santos J, et al Avoiding the needle: A quality improvement program introducing apixaban for
extended thromboprophylaxis after major gynecologic cancer surgery.
Gynecol Oncol. 2024;188:131-139. PubMedAbstract available
RODRIGUEZ GC, Yozwiak M, Nelson OL, Zhang HH, et al The karyometric signature is altered in fallopian tubes with serous tubal
intraepithelial carcinoma.
Gynecol Oncol. 2024;186:110-116. PubMedAbstract available
June 2024
FUMAGALLI D, Sonik R, De Vitis LA, Rossi V, et al Evaluating nutrition in advanced ovarian cancer: which biomarker works best?
Gynecol Oncol. 2024;188:97-102. PubMedAbstract available
MEADE CE, Sinnott JA, Backes FJ, Cosgrove CM, et al Associations between race and ethnicity and treatment setting among gynecologic
cancer patients.
Gynecol Oncol. 2024;188:111-119. PubMedAbstract available
MIRZA MR, Tandaric L, Henriksen JR, Maenpaa J, et al NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the
anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer.
Gynecol Oncol. 2024;188:103-110. PubMedAbstract available
KA K, Cordoba A, Cagetti LV, Schiappa R, et al Preoperative brachytherapy of early-stage cervical cancer: A multicenter study by
the SFRO brachytherapy group.
Gynecol Oncol. 2024;188:90-96. PubMedAbstract available
KOCIAN R, Kohler C, Bajsova S, Jarkovsky J, et al Sentinel lymph node pathological ultrastaging: Final outcome of the Sentix
prospective international study in patients with early-stage cervical cancer.
Gynecol Oncol. 2024;188:83-89. PubMedAbstract available
MANNING-GEIST BL, Sullivan MW, Zhou Q, Iasonos A, et al Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring
new therapeutic possibilities.
Gynecol Oncol. 2024;188:52-57. PubMedAbstract available
KOH B, Ryu JY, Noh JJ, Hwang JR, et al Anti-cancer effects of benzimidazole derivative BNZ-111 on paclitaxel-resistant
ovarian cancer.
Gynecol Oncol. 2024;188:60-70. PubMedAbstract available
EKMANN-GADE AW, Hogdall CK, Seibaek L, Noer MC, et al Corrigendum to "Incidence, treatment, and survival trends in older versus younger
women with epithelial ovarian cancer from 2005 to 2018: A nationwide Danish
study" [Gynecologic Oncology 164/1(2022) 120-128].
Gynecol Oncol. 2024;188:58-59. PubMed
BHATNAGAR AR, Ghanem AI, Alkamachi B, Allo G, et al The prognostic impact of substantial lymphovascular space invasion in women with
node negative FIGO stage I uterine carcinoma.
Gynecol Oncol. 2024;188:44-51. PubMedAbstract available
GARZON S, Calio A, Ferrari FA, Iannicello CQ, et al Uterine perivascular epithelioid cell tumors (PEComa) and the accuracy of
proposed classification systems in predicting the malignant versus non-malignant
behavior.
Gynecol Oncol. 2024;188:35-43. PubMedAbstract available
CHEN H, Chen Y, Zheng A, Tan X, et al Is pharmacologic venous Thromboprophylaxis necessary for patients undergoing
minimally invasive surgery for endometrial Cancer? A systematic review and
Meta-analysis.
Gynecol Oncol. 2024;188:27-34. PubMedAbstract available
WALKER CA, Edwards C, McIntire D, Makepeace L, et al Predicting VTE and utility of thromboprophylaxis in metastatic and recurrent
cervical cancer.
Gynecol Oncol. 2024;188:22-26. PubMedAbstract available
PATEL KB, Escamilla V, Wolfe L, Morris T, et al Food deserts, endometrial cancer survivors, and healthy food access: Is it
equitable in rural America? - A geospatial analysis.
Gynecol Oncol. 2024;188:8-12. PubMedAbstract available
FLANIGAN MR, Bell SG, Donovan HS, Zhao J, et al Variables impacting prolonged post-anesthesia care unit length of stay in
gynecologic cancer patients in the era of same day minimally invasive
hysterectomy.
Gynecol Oncol. 2024;186:211-215. PubMedAbstract available
BORHO L, Bao R, Elishaev E, Dinkins KD, et al Association of allostatic load with overall survival in epithelial ovarian
cancer.
Gynecol Oncol. 2024;186:204-210. PubMedAbstract available
CHAN JK, Tewari K, Monk BJ, Herzog TJ, et al Biomarker guidance in selection among breakthrough treatment options in advanced
and recurrent endometrial cancer.
Gynecol Oncol. 2024;187:249-252. PubMed
MAKKER V, Perez-Fidalgo JA, Valabrega G, Hamilton E, et al Long-term follow-up of efficacy and safety of selinexor maintenance treatment in
patients with TP53wt advanced or recurrent endometrial cancer: A subgroup
analysis of the ENGOT-EN5/GOG-3055/SIENDO study.
Gynecol Oncol. 2024 Jun 3:S0090-8258(24)00234. PubMedAbstract available
AISAGBONHI O, Ghlichloo I, Hong DS, Roma A, et al Comprehensive next-generation sequencing identifies novel putative pathogenic or
likely pathogenic germline variants in patients with concurrent tubo-ovarian and
endometrial serous and endometrioid carcinomas or precursors.
Gynecol Oncol. 2024;187:241-248. PubMedAbstract available
VALABREGA G, Pothuri B, Oaknin A, Graybill WS, et al Efficacy and safety of niraparib in patients aged 65 years and older with
advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Gynecol Oncol. 2024;187:128-138. PubMedAbstract available
O'CONNOR RM, Huang DS, Rimel BJ, Kim KH, et al Unmet financial needs among patients crowdfunding to support gynecologic cancer
care.
Gynecol Oncol. 2024;186:199-203. PubMedAbstract available
BERTON D, Pautier P, Lorusso D, Gennigens C, et al Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with
recurrent microsatellite instability-high or deficient mismatch repair
endometrial cancer: Final safety and efficacy results from cohort H of the
POD1UM-101 phase I stud
Gynecol Oncol. 2024;186:191-198. PubMedAbstract available
CHALIF J, Kistenfeger Q, Fulton J, Morton M, et al Diagnosis and management of gastric-type endocervical adenocarcinoma: A case
report and review of the literature.
Gynecol Oncol. 2024;185:165-172. PubMedAbstract available
SCALISE CB, Kincaid K, Thigpen H, Moore J, et al A spatial proteomic study of platinum refractory HGSOC implicates dual AKT and
WNT activity linked to an immunosuppressive tumor microenvironment.
Gynecol Oncol. 2024;185:83-94. PubMedAbstract available
FEINBERG J, Da Cruz Paula A, da Silva EM, Pareja F, et al Adenoid cystic carcinoma of the Bartholin's gland is underpinned by MYB- and
MYBL1- rearrangements.
Gynecol Oncol. 2024;185:58-67. PubMedAbstract available
HOHN AK, Forberger M, Alfaraidi M, Gilks CB, et al High concordance of molecular subtyping between pre-surgical biopsy and surgical
resection specimen (matched-pair analysis) in patients with vulvar squamous cell
carcinoma using p16- and p53-immunostaining.
Gynecol Oncol. 2024;185:17-24. PubMedAbstract available
May 2024
FRANCO S, Godley LA Myeloid neoplasms in individuals with breast and ovarian cancer and the
association with deleterious germline variants.
Gynecol Oncol. 2024;187:235-240. PubMedAbstract available
LOF P, van Soolingen NJ, Piek JMJ, Aarts JWM, et al Preferences and considerations for interval cytoreductive surgery in advanced
ovarian cancer: The patient's perspective.
Gynecol Oncol. 2024;187:227-234. PubMedAbstract available
PITIYARACHCHI O, Ansell PJ, Coleman RL, Dinh MH, et al Homologous recombination deficiency should be tested for in patients with
advanced stage high-grade serous ovarian cancer aged 70 years and over.
Gynecol Oncol. 2024;187:221-226. PubMedAbstract available
YUAN G, Zhang K, Zheng H, Wu Y, et al Suvemcitug plus chemotherapy for platinum-resistant epithelial ovarian, fallopian
tube and primary peritoneal cancer: A phase 1b dose-escalation trial.
Gynecol Oncol. 2024;187:212-220. PubMedAbstract available
CARBALLO EV, Kim KH, Penn CA Trends in estimated PARP inhibitor eligibility and benefit among US epithelial
ovarian cancer patients.
Gynecol Oncol. 2024;187:204-211. PubMedAbstract available
OSAZUWA-PETERS OL, Greiner MA, Kaufman BG, Zambrano Guevara LM, et al ACO leakage among gynecologic cancer patients: Incidence, predictors, and impact
on annual Medicare expenditure.
Gynecol Oncol. 2024;187:184-191. PubMedAbstract available
PERSSON J, Luhrs O, Geppert B, Ekdahl L, et al A prospective study evaluating an optimized sentinel node algorithm in early
stage cervical cancer: The PROSACC-study.
Gynecol Oncol. 2024;187:178-183. PubMedAbstract available
MARCHETTI C, Ataseven B, Perrone AM, Cassani C, et al Clinical characteristics and survival outcome of early-stage, high-grade, serous
tubo-ovarian carcinoma according to BRCA mutational status.
Gynecol Oncol. 2024;187:170-177. PubMedAbstract available
LARAJA A, Connor Y, Poulson MR The effect of urban racial residential segregation on ovarian cancer diagnosis,
treatment, and survival.
Gynecol Oncol. 2024;187:163-169. PubMedAbstract available
FERRIS JS, Prest MT, Hur C, Chen L, et al Trends in uterine cancer incidence in the United States: The contribution of age,
period and cohort effects.
Gynecol Oncol. 2024;187:151-162. PubMedAbstract available
ZENATRI M, Perennec T, Michon C, Gernier F, et al Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral
neuropathy in ovarian cancer survivors: A substudy of the GINECO Vivrovaire
study.
Gynecol Oncol. 2024;187:139-144. PubMedAbstract available
HUNSBERGER KS, Treiman S, Monk BJ, Tewari KS, et al A systematic review of stage IVA cervical cancer treatment: Challenges in the
management of an understudied group.
Gynecol Oncol. 2024;187:120-127. PubMedAbstract available
LIU JF, Xiong N, Wenham RM, Wahner-Hendrickson A, et al A phase 2 trial exploring the significance of homologous recombination status in
patients with platinum sensitive or platinum resistant relapsed ovarian cancer
receiving combination cediranib and olaparib.
Gynecol Oncol. 2024;187:105-112. PubMedAbstract available
ROSATI A, De Rose AM, Gallotta V, Giannarelli D, et al Feasibility and operative outcomes of surgery in the liver area in advanced
ovarian cancer.
Gynecol Oncol. 2024;187:98-104. PubMedAbstract available
PIEDIMONTE S, Murray C, Atenafu EG, Rouzbahman M, et al Correlating the KELIM (CA125 elimination rate constant K) score and the
chemo-response score as predictors of chemosensitivity in patients with advanced
ovarian carcinoma.
Gynecol Oncol. 2024;187:92-97. PubMedAbstract available
KIM JH, Han KH, Park EY, Kim ET, et al Efficacy of immune-checkpoint inhibitors combined with cytotoxic chemotherapy in
advanced or recurrent endometrial cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2024;187:85-91. PubMedAbstract available
FILIPPOVA OT, Boecking K, Broach V, Gardner GJ, et al Trends in specific procedures performed at the time of cytoreduction for ovarian
cancer: Is interval debulking surgery truly less radical? A Memorial Sloan
Kettering Cancer Center Team Ovary study.
Gynecol Oncol. 2024;187:80-84. PubMedAbstract available
LIANG S, Ge H, Zhou S, Tang J, et al Prognostic factors of 87 ovarian yolk sac tumor (OYST) patients and molecular
characteristics of persistent and recurrent OYST.
Gynecol Oncol. 2024;187:64-73. PubMedAbstract available
CHIBA Y, Kojima Y, Yazaki S, Yoshida H, et al Trop-2 expression and the tumor immune microenvironment in cervical cancer.
Gynecol Oncol. 2024;187:51-57. PubMedAbstract available
GONZALEZ-MARTIN A, Chung HC, Saada-Bouzid E, Yanez E, et al Lenvatinib plus pembrolizumab for patients with previously treated advanced
ovarian cancer: Results from the phase 2 multicohort LEAP-005 study.
Gynecol Oncol. 2024;186:182-190. PubMedAbstract available
MATSUO K, Chen L, Klar M, Lee MW, et al Prognostic performance of the 2023 FIGO staging schema for endometrial cancer.
Gynecol Oncol. 2024;187:37-45. PubMedAbstract available
MITRIC C, Sayyid RK, Fleshner NE, Look Hong NJ, et al Hysterectomy versus chemotherapy for low-risk non-metastatic gestational
trophoblastic neoplasia (GTN): A cost-effectiveness analysis.
Gynecol Oncol. 2024;187:30-36. PubMedAbstract available
PAPPAS TC, Roy Choudhury M, Chacko BK, Twiggs LB, et al Neural network-derived multivariate index assay demonstrates effective clinical
performance in longitudinal monitoring of ovarian cancer risk.
Gynecol Oncol. 2024;187:21-29. PubMedAbstract available
DEMIRKIRAN C, Greenman M, Bellone S, McNamara B, et al Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in
combination with FAK inhibition in uterine carcinosarcomas.
Gynecol Oncol. 2024;187:12-20. PubMedAbstract available
RING KL, Duska LR How far is too far? Cancer prevention and clinical trial enrollment in
geographically underserved patient populations.
Gynecol Oncol. 2024;184:8-15. PubMedAbstract available
MACCHIA G, Cilla S, Pezzulla D, Campitelli M, et al Efficacy of stereotactic body radiotherapy and response prediction using
artificial intelligence in oligometastatic gynaecologic cancer.
Gynecol Oncol. 2024;184:16-23. PubMedAbstract available
April 2024
HOLTZMAN S, McCarthy L, Estevez SL, Lee JA, et al Walking the tightrope: Fertility preservation among hereditary breast and ovarian
Cancer syndrome Previvors.
Gynecol Oncol. 2024;186:176-181. PubMedAbstract available
JIANG Z, Zhu M, Zhang L, Cui H, et al Antitumor immunity and prognosis value elicited by FAT3 and LRP1B co-mutation in
endometrial cancer.
Gynecol Oncol. 2024;187:1-11. PubMedAbstract available
HOFFMAN M, Dunsmore V, Cliby W, Chi D, et al Surgical training of gynecologic oncology fellows: Long-term trends and
implications for future education.
Gynecol Oncol. 2024;184:254-258. PubMedAbstract available
SMITH AJB, O'Brien C, Haggerty A, Ko EM, et al "Having cancer is very expensive": A qualitative study of patients with ovarian
cancer and PARP inhibitor treatment.
Gynecol Oncol. 2024;186:170-175. PubMedAbstract available
CHALIF J, Chambers LM, Yao M, Kuznicki M, et al Extended-duration antibiotics are not associated with a reduction in surgical
site infection in patients with ovarian cancer undergoing cytoreductive surgery
with large bowel resection.
Gynecol Oncol. 2024;186:161-169. PubMedAbstract available
PENG H, Jiang J, Li L, Hao Z, et al Mismatch repair deficiency and abnormal p53 expression has significant predictive
value for progesterone resistance and endometrial tumorigenesis in patients with
endometrial atypical hyperplasia receiving fertility-preserving treatment.
Gynecol Oncol. 2024;186:154-160. PubMedAbstract available
ALGERA MD, van Driel WJ, Slangen BFM, Wouters MWJM, et al Effect of surgical volume on short-term outcomes of cytoreductive surgery for
advanced-stage ovarian cancer: A population-based study from the Dutch
Gynecological Oncology Audit.
Gynecol Oncol. 2024;186:144-153. PubMedAbstract available
PATEL JM, Hermann CE, Growdon WB, Aviki E, et al ChatGPT accurately performs genetic counseling for gynecologic cancers.
Gynecol Oncol. 2024;183:115-119. PubMedAbstract available
WANG CC, Grubbs A, Foley OW, Bharadwa S, et al The activity advantage: Objective measurement of preoperative activity is
associated with postoperative recovery and outcomes in patients undergoing
surgery with gynecologic oncologists.
Gynecol Oncol. 2024;186:137-143. PubMedAbstract available
ZHAO Z, Wang J, Kong W, Fang Z, et al Intermittent energy restriction inhibits tumor growth and enhances paclitaxel
response in a transgenic mouse model of endometrial cancer.
Gynecol Oncol. 2024;186:126-136. PubMedAbstract available
NELSON AT, Harris AK, Watson D, Kamihara J, et al Outcomes in ovarian Sertoli-Leydig cell tumor: A report from the International
Pleuropulmonary Blastoma/DICER1 and Ovarian and Testicular Stromal Tumor
Registries.
Gynecol Oncol. 2024;186:117-125. PubMedAbstract available
EHMANN S, Lam C, Zhou Q, Iasonos A, et al Secondary cytoreductive surgery and oncologic outcomes in the era of targeted
maintenance therapy for recurrent, platinum-sensitive ovarian cancer.
Gynecol Oncol. 2024;186:104-109. PubMedAbstract available
ESPINOSA I, D'Angelo E, Prat J Endometrial carcinoma: 10 years of TCGA (the cancer genome atlas): A critical
reappraisal with comments on FIGO 2023 staging.
Gynecol Oncol. 2024;186:94-103. PubMedAbstract available
MATSUO K, Huang Y, Matsuzaki S, Vallejo A, et al Cesarean hysterectomy for placenta accreta spectrum: Surgeon specialty-specific
assessment.
Gynecol Oncol. 2024;186:85-93. PubMedAbstract available
GITTO SB, Ihewulezi CJN, Powell DJ Jr Adoptive T cell therapy for ovarian cancer.
Gynecol Oncol. 2024;186:77-84. PubMedAbstract available
DAHM-KAHLER P, Radestad AF, Holmberg E, Borgfeldt C, et al Has time to chemotherapy from primary debulking surgery in advanced ovarian
cancer an impact on survival? - A population-based nationwide SweGCG study.
Gynecol Oncol. 2024;186:69-76. PubMedAbstract available
GIEN LT, Enserro DM, Block MS, Waggoner S, et al Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma
of the ovary: An NRG oncology study GY016.
Gynecol Oncol. 2024;186:61-68. PubMedAbstract available
SAYLOR KW, Fernandes EQ, Adams M, Paraghamian S, et al Predictors of germline genetic testing referral and completion in ovarian cancer
patients at a Comprehensive Cancer Center.
Gynecol Oncol. 2024;186:53-60. PubMedAbstract available
KOPELMAN ZA, Tian C, Tumas J, Phippen NT, et al Disease progression, survival, and molecular disparities in Black and White
patients with endometrioid endometrial carcinoma in real-world registries and
GOG/NRG oncology randomized phase III clinical trials.
Gynecol Oncol. 2024;183:103-114. PubMedAbstract available
HOLLIS RL, Elliott R, Dawson JC, Ilenkovan N, et al High throughput screening identifies dasatinib as synergistic with trametinib in
low grade serous ovarian carcinoma.
Gynecol Oncol. 2024;186:42-52. PubMedAbstract available
VESZTERGOM D, Teglas G, Bahrehmand K, Torok A, et al Reducing radicality in fertility-sparing surgery is associated with improved in
vitro fertilization outcome in early-stage cervical cancer: A national
retrospective study.
Gynecol Oncol. 2024;186:35-41. PubMedAbstract available
Introduction to SGO VSI.
Gynecol Oncol. 2024;183:A7. PubMed
RIEDINGER CJ, Barrington DA, Nagel CI, Khadraoui WK, et al Retraction notice to "Cost-effectiveness of chemotherapy and dostarlimab for
advanced or recurrent endometrial cancer" [Gynecologic Oncology 183 (2024)
78-84].
Gynecol Oncol. 2024;183:R1. PubMed
March 2024
MONTEMORANO L, Shultz ZB, Farooque A, Hyun M, et al TP53 mutations and the association with platinum resistance in high grade serous
ovarian carcinoma.
Gynecol Oncol. 2024;186:26-34. PubMedAbstract available
SHEN X, Wang J, Deng B, Chen S, et al High-dose ascorbate exerts anti-tumor activities and improves inhibitory effect
of carboplatin through the pro-oxidant function pathway in uterine serous
carcinoma cell lines.
Gynecol Oncol. 2024;183:93-102. PubMedAbstract available
SALINARO JR, Rossi EC, Penvose KN, Zhang Y, et al Delayed publication of clinical trials in gynecologic oncology.
Gynecol Oncol. 2024;183:74-77. PubMedAbstract available
HUANG Y, Rauh-Hain JA, McCoy TH, Hou JY, et al Comparing survival of older ovarian cancer patients treated with neoadjuvant
chemotherapy versus primary cytoreductive surgery: Reducing bias through machine
learning.
Gynecol Oncol. 2024;186:9-16. PubMedAbstract available
DESRAVINES N, Hazimeh D, Desjardins MR, Wethington SL, et al Healthcare utilization in women diagnosed with endometrial cancer: A survey-based
study.
Gynecol Oncol. 2024;186:1-8. PubMedAbstract available
WILLIAMS-BROWN MY, Summey RM, Newtson A, Burke W, et al System-level recommendations for improved wellness for gynecologic oncologists: A
Society of Gynecologic Oncology Review.
Gynecol Oncol. 2024;183:85-92. PubMedAbstract available
RIEDINGER CJ, Barrington DA, Nagel CI, Khadraoui WK, et al Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent
endometrial cancer.
Gynecol Oncol. 2024;183:78-84. PubMedAbstract available
KIM NK, Choi CH, Seong SJ, Lee JM, et al Treatment outcomes according to various progestin treatment strategies in
patients with atypical hyperplasia/endometrial intraepithelial neoplasia -
Multicenter retrospective study (KGOG2033).
Gynecol Oncol. 2024;183:68-73. PubMedAbstract available
PASSARELLI A, Carbone V, Pignata S, Mazzeo R, et al Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of
clinical activity.
Gynecol Oncol. 2024;183:61-67. PubMedAbstract available
LIANG MI, Dholakia JD, Lee GM, Wang L, et al Dedicated financial hardship screening adds value to routine distress screening
among gynecologic cancer patients.
Gynecol Oncol. 2024;183:53-60. PubMedAbstract available
AHSAN MD, Webster EM, Wolfe IA, McGonigle R, et al Personalized survivorship care: Routine breast cancer risk assessment in the
gynecologic oncology clinic.
Gynecol Oncol. 2024;183:47-52. PubMedAbstract available
HARTMAN YAW, Kenkhuis MF, Stelten S, Brouwer CG, et al Demographic, clinical, and sociocognitive determinants related to physical
activity and dietary intake in patients with ovarian cancer: A cross-sectional
study.
Gynecol Oncol. 2024;183:39-46. PubMedAbstract available
LEVINE BJ Letter re: Ban et al., A personalized probabilistic approach to ovarian cancer
diagnostics.
Gynecol Oncol. 2024 Mar 15:S0090-8258(24)00155. PubMed
ROSS DH, Gomez K, Harmon G, Mysz ML, et al Evaluating outcomes and toxicities for a newly implemented MRI-based
brachytherapy program for cervical cancer.
Gynecol Oncol. 2024;183:33-38. PubMedAbstract available
CACCIOTTOLA L, Camboni A, Gatti E, Marbaix E, et al Fertility potential and safety assessment of residual ovarian cortex in young
women diagnosed with epithelial borderline and early-stage malignant ovarian
tumors.
Gynecol Oncol. 2024;183:15-24. PubMedAbstract available
BYRNE M, Sia TY, Fong C, Khurram A, et al Mainstreaming in parallel with ovarian cancer tumor testing to improve genetic
testing uptake.
Gynecol Oncol. 2024 Mar 14:S0090-8258(24)00144. PubMedAbstract available
GASS P, Thiel FC, Haberle L, Ackermann S, et al Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III
study to compare the effects of paclitaxel and topotecan with those of cisplatin
and topotecan in the treatment of patients with recurrent and persistent cervical
cancer.
Gynecol Oncol. 2024;183:25-32. PubMedAbstract available
BJERRE TRENT PK, Nordskar NJ, Wangen KR, Engeskaug MI, et al Corrigendum to "Self-reported lower extremity lymphedema and quality of life
after surgical staging of endometrial carcinoma: A population based
cross-sectional study" [Gynecologic Oncology 175 (2023) 72-80].
Gynecol Oncol. 2024;183:7-8. PubMed
GLASER GE, Maddy B, Kumar A, Ishitani K, et al Impact of pharmacogenomic profiles on post-surgical pain following laparotomy for
gynecologic pathology.
Gynecol Oncol. 2024;183:9-14. PubMedAbstract available
PANDYA D, Tomita S, Rhenals MP, Swierczek S, et al Mutations in cancer-relevant genes are ubiquitous in histologically normal
endometrial tissue.
Gynecol Oncol. 2024;185:194-201. PubMedAbstract available
GAFFNEY D, Matias-Guiu X, Mutch D, Scambia G, et al 2023 FIGO staging system for endometrial cancer: The evolution of the revolution.
Gynecol Oncol. 2024;184:245-253. PubMedAbstract available
RICHARDSON DL, Moore KN, Vergote I, Gilbert L, et al Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha
(FRalpha)-targeting antibody-drug conjugate, in combination with carboplatin and
bevacizumab in patients with platinum-sensitive ovarian cancer.
Gynecol Oncol. 2024;185:186-193. PubMedAbstract available
NOGUEIRA-RODRIGUES A, Giannecchini GV, Secord AA Real world challenges and disparities in the systemic treatment of ovarian
cancer.
Gynecol Oncol. 2024;185:180-185. PubMedAbstract available
OLAWAIYE AB 2023 FIGO staging for endometrial cancer, a look at both sides of the coin.
Gynecol Oncol. 2024;184:243-244. PubMed
EJAREDAR M, Ruzycki SM, Glazer TS, Trudeau P, et al Implementation of a surgical site infection prevention bundle in gynecologic
oncology patients: An enhanced recovery after surgery initiative.
Gynecol Oncol. 2024;185:173-179. PubMedAbstract available
GLASER GE, Dowdy SC Sentinel lymph node biopsy in high-risk endometrial cancer: The denouement.
Gynecol Oncol. 2024;182:A1-A2. PubMed
CHEN W, Xie J, Gao C, Zhang C, et al Hypertension associated with niraparib in cancer patients: A pharmacovigilance
analysis based on the FAERS database and meta-analysis of randomized controlled
trials.
Gynecol Oncol. 2024;182:108-114. PubMedAbstract available
February 2024
CAO B, Li Y, Liu Y, Chen X, et al A multi-center study to predict the risk of intraoperative hypothermia in
gynecological surgery patients using preoperative variables.
Gynecol Oncol. 2024;185:156-164. PubMedAbstract available
CHEN Y, Yang J, Wan Y, Li Q, et al DEAR model in overweight endometrial cancer patients undergoing fertility-sparing
treatment: A randomized controlled trial.
Gynecol Oncol. 2024;185:148-155. PubMedAbstract available
COSTALES AB, Crane EK, Chambers L, Yao M, et al Laparoscopic predictability of minimally invasive interval debulking in advanced
ovarian cancer: The MIID-SOC trial.
Gynecol Oncol. 2024;185:143-147. PubMedAbstract available
SALMAN L, Covens A, Vicus D, Podolsky S, et al The role of surgeon specialty in management and survival of malignant ovarian
germ cell tumors: A population-based study.
Gynecol Oncol. 2024;185:138-142. PubMedAbstract available
RONCOLATO F, King MT, O'Connell RL, Lee YC, et al Hidden in plain sight - Survival consequences of baseline symptom burden in women
with recurrent ovarian cancer.
Gynecol Oncol. 2024;185:128-137. PubMedAbstract available
AGUSTI N, Kanbergs A, Nitecki R Potential of molecular classification to guide fertility-sparing management among
young patients with endometrial cancer.
Gynecol Oncol. 2024;185:121-127. PubMedAbstract available
MCNAMARA B, Demirkiran C, Hartwich TMP, Bellone S, et al Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK
inhibition in low grade serous ovarian cancer.
Gynecol Oncol. 2024 Feb 9:S0090-8258(24)00043. PubMedAbstract available
APPLEBAUM AJ The importance of family-focused care in the setting of advanced gynecological
cancers.
Gynecol Oncol. 2024;181:A1-A2. PubMed
PELTECU G Eugen Bogdan Aburel, a pioneer of fertility sparing surgery.
Gynecol Oncol. 2024;181:40-45. PubMedAbstract available
VASTA FM, Cormio G, Cassani C, Bergamini A, et al Reproductive outcomes after conservative treatment in early and advanced stage
MOGCTs.
Gynecol Oncol. 2024;181:28-32. PubMedAbstract available
TAYLOR DD, Gercel-Taylor C, Parker LP Retraction notice to "Patient-derived tumor reactive antibodies as diagnostic
markers for ovarian cancer" [Gynecologic Oncology 115 (2009) 112-120].
Gynecol Oncol. 2024;181:186. PubMed
January 2024
FADER AN, Ko EM, Pollock BD, Blank SV, et al An SGO commentary: U.S. News and World Report gynecologic oncology procedural
ratings-Do they reflect high-quality care?
Gynecol Oncol. 2024 Jan 25:S0090-8258(24)00002. PubMedAbstract available
October 2023
KIM JH, Kim SI, Park EY, Ha HI, et al Impact of postoperative residual disease on survival in epithelial ovarian cancer
with consideration of recent frontline treatment advances: A systematic review
and meta-analysis.
Gynecol Oncol. 2023;179:24-32. PubMedAbstract available